Evidence map›Paper›PMID 34074001›Full record

ArticleMolecules (Basel, Switzerland)2021

Proteomic Analysis of Zeb1 Interactome in Breast Carcinoma Cells.

Sergey E Parfenyev, Sergey V Shabelnikov, Danila Y Pozdnyakov, Olga O Gnedina, Leonid S Adonin, Nickolai A Barlev, Alexey G Mittenberg

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. p53 Affects Zeb1 Interactome of Breast Cancer Stem Cells.International journal of molecular sciences · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sergey E ParfenyevInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Sergey V ShabelnikovInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Danila Y PozdnyakovInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Olga O GnedinaInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.ORCID 0000-0003-2650-4568
Leonid S AdoninMoscow Institute of Physics and Technology, 141700 Dolgoprudny, Russia.
Nickolai A BarlevInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Alexey G MittenbergInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.ORCID 0000-0002-3675-0597
Institute of Cytology · RUMoscow Institute of Physics and Technology · RU

Funding

Russian Foundation for Basic Research 18-29-09073-MKRussian Government Program for the Recruitment of the leading scientists into the Russian Institutions of Higher Education 14. W03.31.0029Russian Scientific Foundation 20-15-00189
6 · The paper itself

Abstract

Breast cancer is the most frequently diagnosed malignant neoplasm and the second leading cause of cancer death among women. Epithelial-to-mesenchymal Transition (EMT) plays a critical role in the organism development, providing cell migration and tissue formation. However, its erroneous activation in malignancies can serve as the basis for the dissemination of cancer cells and metastasis. The Zeb1 transcription factor, which regulates the EMT activation, has been shown to play an essential role in malignant transformation. This factor is involved in many signaling pathways that influence a wide range of cellular functions via interacting with many proteins that affect its transcriptional functions. Importantly, the interactome of Zeb1 depends on the cellular context. Here, using the inducible expression of Zeb1 in epithelial breast cancer cells, we identified a substantial list of novel potential Zeb1 interaction partners, including proteins involved in the formation of malignant neoplasms, such as ATP-dependent RNA helicase DDX17and a component of the NURD repressor complex, CTBP2. We confirmed the presence of the selected interactors by immunoblotting with specific antibodies. Further, we demonstrated that co-expression of Zeb1 and CTBP2 in breast cancer patients correlated with the poor survival prognosis, thus signifying the functionality of the Zeb1-CTBP2 interaction.

Indexed as

ProteomicsBreast NeoplasmsCell Line, TumorEpithelial-Mesenchymal TransitionFemaleHumansProtein BindingSignal TransductionZinc Finger E-box-Binding Homeobox 1ZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1breast cancerepithelial to mesenchymal transition (EMT)metastasisZeb1

Identifiers

PMID34074001
PMCPMC8197395
OpenAlexW3165435582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.